Modelos europeos de telemedicina, como el servicio finlandés Medilux, permiten realizar consultas médicas online mediante un cuestionario clínico, sin acudir a una consulta presencial.

Bilateral Mammary Artery Graft to Reduce the Chance of Repeat Revascularization

According to previous studies, patients receiving bilateral internal mammary artery conduits during coronary artery bypass grafting have better survival than those receiving a single internal mammary artery. The reason behind this remains unclear, let alone whether there really is lower repeat revascularization rate.

Doble puente mamario para reducir la chance de nuevas revascularizaciones

This analysis compared timing, frequency, and type of repeat coronary revascularization among patients receiving single vs. bilateral internal mammary artery conduits.


Read also: Myocardial Revascularization Surgery: One or Two Internal-Thoracic-Artery Grafts?”.


The study included 47,984 consecutive patients undergoing bypass revascularization surgery in 7 centers between 1992 and 2014. 1,482 of these patients received bilateral internal mammary artery conduits.

 

To compare them, patients were propensity matched, which left 1,297 patients in each branch (bilateral vs. single internal mammary artery) for final analyzis. Primary end point was freedom from repeat revascularization.


Read also: Additional Benefit from Radial Artery Graft in Myocardial Revascularization Surgery”.


After a 13.2 year follow up, well matched by age, comorbidities, ventricular function, etc., patients showed that bilateral internal mammary artery conduits are associated with higher freedom from revascularization, compared against single mammary artery conduits (HR= 0.78, CI 95%, 0.65 to 0.94; p=0.009). 19.4% (n=252) of patients in the single mammary artery branch required repeat revascularization at follow up vs. 15.1% (n=196) of patients with bilateral mammary artery conduits (p=0.004).

 

The vast majority of revascularization procedures were PCIs for both groups, the most frequently intervened being the right coronary and the circumflex.

 

In addition, bilateral internal mammary artery conduits were associated with a reduction in all-cause mortality at 12 years (HR, 0.79; p=0.001) and there was no increase in inhospital mortality rate.

 

Conclusion

Bilateral mammary artery conduits were associated with a reduction in repeat revascularization rate and better survival rate at long term, which is why it should be considered more frequently in myocardial revascularization surgery.

 

Editorial Comment

The NEJM has recently published the 5 year ART trial follow up, which randomized CABG patients to bilateral vs. single internal mammary artery grafts. This study, the largest on this matter, was not able to show differences at 5 years, though outcomes at 10 years remain pending. There was increased morbidity among patients receiving bilateral internal mammary artery grafts (sternal infections and need of sternal reconstruction).

 

Original title: Does Use of Bilateral Internal Mammary Artery Grafting Reduce Long-Term Risk of Repeat Coronary Revascularization? A Multicenter Analysis.

Reference: Alexander Iribarne et al. Circulation. 2017;136:1676–1685.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

EuroPCR 2026 | 10-Year Left Main PCI: When Survival Is Similar, Should the Less Invasive Strategy Prevail?

The primary goal of revascularization in left main coronary artery disease (LMCA) is to improve survival. However, debate continues regarding whether, in anatomically suitable...

EuroPCR 2026 | TAVI and Coronary Artery Disease: FFR-Guided PCI Showed Better Outcomes Than an Angiography-Guided Strategy

In patients undergoing TAVI, the concomitant presence of coronary artery disease continues to generate debate: whether coronary lesions should be treated before, during, or...

EuroPCR 2026 | Evolocumab Reduces Cardiovascular Events in Patients With Prior PCI Without Previous Myocardial Infarction: VESALIUS-CV Results

This presentation, delivered by Dr. Brian A. Bergmark and colleagues at EuroPCR 2026, detailed the results of the VESALIUS-CV trial, focusing specifically on the...

EuroPCR 2026 | Is It Safe to Stop Aspirin After One Month in MI Patients Undergoing PCI? TARGET-FIRST Analysis

This is a summary of the post-hoc analysis of the TARGET-FIRST study, presented by Dr. Giuseppe Tarantini at EuroPCR 2026, evaluating early aspirin discontinuation...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img
Jornadas Guatemala 2026

Recent Articles

EuroPCR 2026 | TAVI in Women: Do Supra-Annular Valves Offer a True Hemodynamic Advantage?

Women represent a particularly challenging population for TAVI, as they often have smaller aortic annuli, greater frailty, and an increased risk of prosthesis-patient mismatch....

EuroPCR 2026 | TAVI or Surgery in Younger Patients? Quality of Life and 3-Year Outcomes from NOTION-2

The expansion of TAVI into younger and lower surgical-risk populations has sparked a new debate: beyond mortality and stroke, which strategy provides better functional...

EuroPCR 2026 | MELA Registry: Myval Showed Lower Aortic Regurgitation Rates in Patients With Large Aortic Annuli

This presentation, delivered by Dr. Salvatore Giordano at EuroPCR 2026, detailed the results of the MELA Registry, a multicenter study comparing the performance of...